Synethesis and biochemical screening of novel non-purine based xanthine oxidase inhibitors

Abstract

Xanthine oxidase (XO), or xanthine oxidoreductase (XOR), is a complex molybdoflavoenzyme which, in humans, is recognized as the terminal enzyme of purine catabolism, catalysing the hydroxylation of purines to uric acid, overproduction of which usually leads to a pathological condition called hyperuricemia and gout. XO inhibitors (XOI) are proved to be promising urate lowering agents. Purine based XOI (allopurinol) however, are associated with various lethal side effects like hypersensitivity syndrome (Stevens Johnson syndrome and Tissue Epidermal Necrolysis), bone marrow depression, rash etc. On the other hand non-purine based XOI (febuxostat) are found to be safer and effective antihyperuricemic and antigout agents. Present investigation describes synthesis, characterization of some non-purine based compounds and their evaluation for xanthine oxidase inhibitory activity